Dr. Elias Discusses the Future of Androgen Receptors in Breast Cancer

Currently, there is a maturing, randomized phase II study of exemestane, plus or minus, enzalutamide in AR-positive breast cancer, says Elias.

Data have been collected in triple-negative breast cancer with enzalutamide, and Elias says it is fairly compelling. He adds that there is potential action on more aggressive, triple-negative breast cancer, and Elias believes combinations will be particularly significant. Examples include combinations with anti-estrogen therapy and everolimus, anti-estrogen therapy and palbociclib, CDK4/6 inhibitors with enzalutamide, etc.

Anthony D. Elias, MD, professor, Division of Medical Oncology, University of Colorado School of Medicine, discusses the future of androgen receptors in breast cancer.